Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1549. [Epub ahead of print]

PMID:
31318407
2.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
3.

Poliosis Circumscripta: A Mark of Melanoma.

Schollenberger MD, Stein JE, Taube JM, Lipson EJ.

Am J Med. 2019 Jun 23. pii: S0002-9343(19)30524-8. doi: 10.1016/j.amjmed.2019.05.042. [Epub ahead of print] No abstract available.

PMID:
31242438
4.

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L.

Breast Cancer Res. 2019 Jun 13;21(1):72. doi: 10.1186/s13058-019-1156-6.

5.

Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.

Llosa NJ, Luber B, Tam AJ, Smith KN, Siegel N, Awan AH, Fan H, Oke T, Zhang J, Domingue J, Engle EL, Roberts CA, Bartlett BR, Aulakh LK, Thompson ED, Taube JM, Durham JN, Sears CL, Le DT, Diaz LA, Pardoll DM, Wang H, Anders RA, Housseau F.

Clin Cancer Res. 2019 Sep 1;25(17):5250-5259. doi: 10.1158/1078-0432.CCR-19-0114. Epub 2019 May 6.

PMID:
31061070
6.

Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.

Kim AK, Gani F, Layman AJ, Besharati S, Zhu Q, Succaria F, Engle EL, Bhaijee F, Goggins MB, Llosa NJ, Pawlik TM, Yarchoan M, Jaffee EM, Simons HC, Taube JM, Anders RA.

Cancer Immunol Res. 2019 May;7(5):805-812. doi: 10.1158/2326-6066.CIR-18-0499. Epub 2019 Mar 22.

PMID:
30902819
7.

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Mar 6;7(1):63. doi: 10.1186/s40425-019-0547-7.

8.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P.

J Immunother Cancer. 2019 Feb 13;7(1):46. doi: 10.1186/s40425-019-0519-y.

9.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Feb 11;7(1):40. doi: 10.1186/s40425-018-0492-x. Erratum in: J Immunother Cancer. 2019 Mar 6;7(1):63.

10.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL.

J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.

PMID:
30726175
11.

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.

Stein JE, Soni A, Danilova L, Cottrell TR, Gajewski TF, Hodi FS, Bhatia S, Urba WJ, Sharfman WH, Wind-Rotolo M, Edwards R, Lipson EJ, Taube JM.

Ann Oncol. 2019 Apr 1;30(4):589-596. doi: 10.1093/annonc/mdz019.

PMID:
30689736
12.

Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors.

Gong C, Anders RA, Zhu Q, Taube JM, Green B, Cheng W, Bartelink IH, Vicini P, Wang B, Popel AS.

Front Oncol. 2019 Jan 7;8:649. doi: 10.3389/fonc.2018.00649. eCollection 2018.

13.

PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function.

Whelan S, Ophir E, Kotturi MF, Levy O, Ganguly S, Leung L, Vaknin I, Kumar S, Dassa L, Hansen K, Bernados D, Murter B, Soni A, Taube JM, Fader AN, Wang TL, Shih IM, White M, Pardoll DM, Liang SC.

Cancer Immunol Res. 2019 Feb;7(2):257-268. doi: 10.1158/2326-6066.CIR-18-0442. Epub 2019 Jan 18.

PMID:
30659054
14.

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.

Giraldo NA, Nguyen P, Engle EL, Kaunitz GJ, Cottrell TR, Berry S, Green B, Soni A, Cuda JD, Stein JE, Sunshine JC, Succaria F, Xu H, Ogurtsova A, Danilova L, Church CD, Miller NJ, Fling S, Lundgren L, Ramchurren N, Yearley JH, Lipson EJ, Cheever M, Anders RA, Nghiem PT, Topalian SL, Taube JM.

J Immunother Cancer. 2018 Oct 1;6(1):99. doi: 10.1186/s40425-018-0404-0.

15.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
16.

Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma.

Harris-Bookman S, Mathios D, Martin AM, Xia Y, Kim E, Xu H, Belcaid Z, Polanczyk M, Barberi T, Theodros D, Kim J, Taube JM, Burger PC, Selby M, Taitt C, Korman A, Ye X, Drake CG, Brem H, Pardoll DM, Lim M.

Int J Cancer. 2018 Dec 15;143(12):3201-3208. doi: 10.1002/ijc.31661. Epub 2018 Sep 24.

PMID:
30248181
17.

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM.

Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218.

18.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

19.

Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.

Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL.

J Cutan Pathol. 2018 Oct;45(10):764-773. doi: 10.1111/cup.13312. Epub 2018 Jul 24.

PMID:
29943453
20.

PD-L1 expression in medulloblastoma: an evaluation by subgroup.

Martin AM, Nirschl CJ, Polanczyk MJ, Bell WR, Nirschl TR, Harris-Bookman S, Phallen J, Hicks J, Martinez D, Ogurtsova A, Xu H, Sullivan LM, Meeker AK, Raabe EH, Cohen KJ, Eberhart CG, Burger PC, Santi M, Taube JM, Pardoll DM, Drake CG, Lim M.

Oncotarget. 2018 Apr 10;9(27):19177-19191. doi: 10.18632/oncotarget.24951. eCollection 2018 Apr 10.

21.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM.

N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

22.

Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis.

Adler BL, Pezhouh MK, Kim A, Luan L, Zhu Q, Gani F, Yarchoan M, Chen J, Voltaggio L, Parian A, Lazarev M, Lauwers GY, Pawlik TM, Montgomery EA, Jaffee E, Le DT, Taube JM, Anders RA.

J Intern Med. 2018 Jun;283(6):568-577. doi: 10.1111/joim.12744. Epub 2018 Mar 24.

23.

PD-L1 expression in inflammatory myofibroblastic tumors.

Cottrell TR, Duong AT, Gocke CD, Xu H, Ogurtsova A, Taube JM, Belchis DA.

Mod Pathol. 2018 Jul;31(7):1155-1163. doi: 10.1038/s41379-018-0034-6. Epub 2018 Feb 15.

24.

PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.

Cottrell TR, Taube JM.

Cancer J. 2018 Jan/Feb;24(1):41-46. doi: 10.1097/PPO.0000000000000301. Review.

25.

PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.

Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H, Peng H, Fu YX.

J Clin Invest. 2018 Feb 1;128(2):580-588. doi: 10.1172/JCI96061. Epub 2018 Jan 16.

26.

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

Duffield AS, Ascierto ML, Anders RA, Taube JM, Meeker AK, Chen S, McMiller TL, Phillips NA, Xu H, Ogurtsova A, Berger AE, Pardoll DM, Topalian SL, Ambinder RF.

Blood Adv. 2017 Jul 21;1(17):1324-1334. doi: 10.1182/bloodadvances.2017007260. eCollection 2017 Jul 25.

27.

Implications of the tumor immune microenvironment for staging and therapeutics.

Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A.

Mod Pathol. 2018 Feb;31(2):214-234. doi: 10.1038/modpathol.2017.156. Epub 2017 Dec 1. Review.

28.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

29.

Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.

Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA.

Clin Cancer Res. 2017 Dec 1;23(23):7333-7339. doi: 10.1158/1078-0432.CCR-17-0950. Epub 2017 Sep 19.

30.

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA Jr, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM.

Am J Surg Pathol. 2017 Oct;41(10):1381-1389. doi: 10.1097/PAS.0000000000000900.

31.

Melanoma subtypes demonstrate distinct PD-L1 expression profiles.

Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH, Kraft S, Gerstenblith MR, Thompson CL, Honda K, Cuda JD, Eberhart CG, Handa JT, Lipson EJ, Taube JM.

Lab Invest. 2017 Sep;97(9):1063-1071. doi: 10.1038/labinvest.2017.64. Epub 2017 Jul 24.

32.

PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.

Thompson ED, Taube JM, Asch-Kendrick RJ, Ogurtsova A, Xu H, Sharma R, Meeker A, Argani P, Emens LA, Cimino-Mathews A.

Mod Pathol. 2017 Nov;30(11):1551-1560. doi: 10.1038/modpathol.2017.79. Epub 2017 Jul 21.

33.

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC.

J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.

34.

PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.

Sunshine JC, Nguyen PL, Kaunitz GJ, Cottrell TR, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KB, Cornish TC, Lipson EJ, Anders RA, Taube JM.

Clin Cancer Res. 2017 Aug 15;23(16):4938-4944. doi: 10.1158/1078-0432.CCR-16-1821. Epub 2017 Apr 20.

35.

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.

Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A.

Cancer Immunol Res. 2017 May;5(5):417-424. doi: 10.1158/2326-6066.CIR-16-0325. Epub 2017 Apr 14.

36.

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.

Lipson EJ, Lilo MT, Ogurtsova A, Esandrio J, Xu H, Brothers P, Schollenberger M, Sharfman WH, Taube JM.

J Immunother Cancer. 2017 Mar 21;5:23. doi: 10.1186/s40425-017-0228-3. eCollection 2017.

37.

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.

Yanik EL, Kaunitz GJ, Cottrell TR, Succaria F, McMiller TL, Ascierto ML, Esandrio J, Xu H, Ogurtsova A, Cornish T, Lipson EJ, Topalian SL, Engels EA, Taube JM.

JAMA Oncol. 2017 Jul 1;3(7):974-978. doi: 10.1001/jamaoncol.2017.0115.

38.

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II.

JAMA Oncol. 2017 Aug 1;3(8):1051-1058. doi: 10.1001/jamaoncol.2017.0013.

39.

Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.

Ascierto ML, Makohon-Moore A, Lipson EJ, Taube JM, McMiller TL, Berger AE, Fan J, Kaunitz GJ, Cottrell TR, Kohutek ZA, Favorov A, Makarov V, Riaz N, Chan TA, Cope L, Hruban RH, Pardoll DM, Taylor BS, Solit DB, Iacobuzio-Donahue CA, Topalian SL.

Clin Cancer Res. 2017 Jun 15;23(12):3168-3180. doi: 10.1158/1078-0432.CCR-17-0270. Epub 2017 Feb 13.

40.

Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.

Micevic G, Theodosakis N, Taube JM, Bosenberg MW, Rodić N.

Melanoma Res. 2017 Apr;27(2):85-96. doi: 10.1097/CMR.0000000000000315.

41.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

42.

Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H, Esandrio J, Anders RA, Cope L, Pardoll DM, Drake CG, Taube JM.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777. Epub 2016 Nov 11.

43.

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ.

N Engl J Med. 2016 Nov 3;375(18):1749-1755.

44.

Secretory Carcinoma of the Skin Harboring ETV6 Gene Fusions: A Cutaneous Analogue to Secretory Carcinomas of the Breast and Salivary Glands.

Bishop JA, Taube JM, Su A, Binder SW, Kazakov DV, Michal M, Westra WH.

Am J Surg Pathol. 2017 Jan;41(1):62-66.

PMID:
27631515
45.

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.

Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, Netto GJ, Xu H, Pritchard TS, Fan J, Cheadle C, Cope L, Drake CG, Pardoll DM, Taube JM, Topalian SL.

Cancer Immunol Res. 2016 Sep 2;4(9):726-33. doi: 10.1158/2326-6066.CIR-16-0072. Epub 2016 Aug 4.

46.

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.

Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, Netto G, Bivalacqua TJ.

Oncoimmunology. 2016 Feb 18;5(5):e1134412. doi: 10.1080/2162402X.2015.1134412. eCollection 2016 May.

47.

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H, Mathios D, Jackson CM, Harris-Bookman S, Garzon-Muvdi T, Sheu M, Martin AM, Tyler BM, Tran PT, Ye X, Olivi A, Taube JM, Burger PC, Drake CG, Brem H, Pardoll DM, Lim M.

Clin Cancer Res. 2017 Jan 1;23(1):124-136. doi: 10.1158/1078-0432.CCR-15-1535. Epub 2016 Jun 29.

48.

Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system.

Voltaggio L, Cimino-Mathews A, Bishop JA, Argani P, Cuda JD, Epstein JI, Hruban RH, Netto GJ, Stoler MH, Taube JM, Vang R, Westra WH, Montgomery EA.

CA Cancer J Clin. 2016 Sep;66(5):408-36. doi: 10.3322/caac.21350. Epub 2016 Jun 6. Review.

49.

Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.

Mathios D, Ruzevick J, Jackson CM, Xu H, Shah SR, Taube JM, Burger PC, McCarthy EF, Quinones-Hinojosa A, Pardoll DM, Lim M.

J Neurooncol. 2016 May;128(1):183. doi: 10.1007/s11060-016-2130-0. No abstract available.

PMID:
27161248
50.

To Control Site-Specific Skin Gene Expression, Autocrine Mimics Paracrine Canonical Wnt Signaling and Is Activated Ectopically in Skin Disease.

Kim D, Hossain MZ, Nieves A, Gu L, Ratliff TS, Mi Oh S, Park A, Han S, Yang NB, Qi J, Taube JM, Kang S, Garza LA.

Am J Pathol. 2016 May;186(5):1140-50. doi: 10.1016/j.ajpath.2015.12.030. Erratum in: Am J Pathol. 2016 Aug;186(8):2236.

Supplemental Content

Loading ...
Support Center